Papers/PMID:34802788
Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).
Vaccine2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
calciol — increases serum 25-hydroxyvitamin D concentration
Evidence strength: very limited.Findingreplicated ×33“After 12 weeks of cholecalciferol supplementation, mean (SD) 25(OH)D concentration increased from 15.0 (8.0) to 31.0 (7.1) ng/mL, but remained unchanged in the control group (14.0 (7.1) to 11.6 (7.5) mg/mL).”
Quoted verbatim from Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).. - Study
- RCT
- Duration
- 3 months
- Dose
- 28,000 IU cholecalciferol orally weekly for 12 weeks
- Population
- Unvaccinated hemodialysis patients with 25(OH)D insufficiency (<30 ng/mL)
Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).2021PMID:3480278810.1016/j.vaccine.2021.11.029Permalink